Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG004A in Tissue Factor Positive Advanced or Metastatic Solid Tumors
NCT04843709Phase 2Completed
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of MRG004A in solid tumor, sponsored by Lepu Biopharma Co., Ltd.. Started Jul 2021; status: completed.
02
Drugs
MRG004A
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04843709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843709.